



B cell receptor ligation induces display of V-region peptides on MHC class II molecules to T cells

Peter Csaba Huszthy^{a,b,1}, Ramakrishna Prabhu Gopalakrishnan^{a,b}, Johanne Tracey Jacobsen^{b,c}, Ole Audun Werner Haabeth^{b,d}, Geir Åge Løset^{e,f}, Ranveig Braathen^{b,g}, Karl Schenck^h, Anders Aune Tveita^{b,i}, Ludvig Andre Munthe^{a,b,i}, and Bjarne Bogen^{a,b,g,1}

^aInstitute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway; ^bDepartment of Immunology, Oslo University Hospital, 0424 Oslo, Norway; ^cLaboratory of Lymphocyte Dynamics, The Rockefeller University, New York, NY 10065; ^dDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305; ^eDepartment of Biosciences, University of Oslo, N-0316 Oslo, Norway; ^fNextera AS, N-0349 Oslo, Norway; ^gKG Jebsen Centre for Research on Influenza Vaccines, Institute of Clinical Medicine, University of Oslo, N-0316 Oslo, Norway; ^hInstitute of Oral Biology, Faculty of Dentistry, University of Oslo, N-0316 Oslo, Norway; and ⁱKG Jebsen Centre for B cell malignancies, Institute of Clinical Medicine, University of Oslo, N-0316 Oslo, Norway

Edited by Klaus Rajewsky, Max Delbrück Center for Molecular Medicine, Berlin, Germany, and approved November 5, 2019 (received for review February 19, 2019)

The B cell receptors (BCRs) for antigen express variable (V) regions that are enormously diverse, thus serving as markers on individual B cells. V region-derived idiotypic (Id) peptides can be displayed as pId:MHCII complexes on B cells for recognition by CD4⁺ T cells. It is not known if naive B cells spontaneously display pId:MHCII in vivo or if BCR ligation is required for expression, thereby enabling collaboration between Id⁺ B cells and Id-specific T cells. Here, using a mouse model, we show that naive B cells do not express readily detectable levels of pId:MHCII. However, BCR ligation by Ag dramatically increases physical display of pId:MHCII, leading to activation of Id-specific CD4⁺ T cells, extrafollicular T–B cell collaboration and some germinal center formation, and production of Id⁺ IgG. Besides having implications for immune regulation, the results may explain how persistent activation of self-reactive B cells induces the development of autoimmune diseases and B cell lymphomas.

idiotypic-driven T–B collaboration | M315-like BCR | idiotypic peptide: MHCII | V-gene modified mouse model | BCR ligation by antigen

Each B cell expresses unique BCR variable (V) regions due to V(D)J recombination and somatic hypermutation (1). The highly diversified V regions express idiotypic (Id) determinants that can be recognized by antibodies (2) and by CD4⁺ T cells (3).

B lymphoma cells constitutively antigen-process their BCR and present Id peptides on their MHC class II molecules (pId:MHCII) to Id-specific CD4⁺ T cells (4, 5). Consistent with this, Id peptides were eluted from MHC class II molecules of tumor B cells (6). On the basis of these results, it was proposed in 1993 that Id-specific T cells help B cells that display pId:MHCII complexes on their surface (7). Such Id-driven T–B collaboration appears to be limited to rare Id peptides that express somatic mutations or unique N-region sequences (3, 8–11), since T cells are tolerized to germline-encoded V region sequences (8, 12). The existence of Id-driven T–B collaboration has been supported by studies using paired Ig/TCR-transgenic mice in 2 independent models (7, 13, 14). Chronic Id-driven T–B collaboration in these models has been associated with development of SLE-like autoimmune disease (13–16) and even B cell lymphomas (17).

The relevance of Id-driven T–B collaboration to disease development has been supported by recent observations in humans. First, bioinformatic analysis has indicated that human Ig V-regions are enriched for sequences that bind MHC molecules (18). Second, signs of Id-driven T–B collaboration have been observed in multiple sclerosis patients (19–21). Third, evidence of Id-driven T–B collaboration was obtained in chronic lymphatic leukemia (CLL) patients (22). Fourth, Id peptides were readily isolated from MHC class II molecules of mantle cell B lymphomas (23), as well as follicular B cell lymphomas, diffuse large B cell lymphoma, and CLL (24).

As an explanation for the pathogenicity of Id-driven T–B collaboration, it has been hypothesized that autoreactive B cells, in lieu of help from self antigen-specific T cells (that are tolerized), could instead receive help from Id-specific CD4⁺ T cells (13, 25). It was further hypothesized that BCR ligation by self antigen could contribute to such pathogenic Id-driven T–B collaboration (13, 25). In support of the hypothesis, BCR ligation caused a GC reaction and isotype switch; however, the experiments employed memory B cells and Th2 cells, not naive cells (13).

To investigate the unresolved issue of whether BCR ligation is required for Id-dependent collaboration between naive B and T cells in vivo, we have here generated a strain of mice that have a low frequency of B cells with a BCR that (i) can be deliberately ligated by antigen and (ii) contains a particular Id sequence in its V region. The model employs a type of V gene segment-modified mice that yields physiological expression of the Id sequence only subsequent to a Vλ2 → Jλ2 rearrangement in developing B cells. The surface display of pId:MHCII was physically detected by a staining reagent. The results show that naive B cells do not express

Significance

B and T lymphocytes collaborate during immune responses to antigens. B cells use membrane-bound antibody as part of their antigen receptor while T cells use a different receptor that recognizes antigen fragments bound to MHC molecules. We show here that T cells can recognize the variable parts of the B cell receptor when these are presented on MHC molecules. A prerequisite for such receptor cross-talk is that the B cell receptor binds antigen. The cross-talk results in collaboration between B and T cells and production of antibodies directed against the antigen. The findings have implications for basic immune regulation. The results may also help us understand the mechanism behind the development of SLE-like autoimmune diseases and B cell lymphomas.

Author contributions: P.C.H., J.T.J., and B.B. designed research; P.C.H., R.P.G., J.T.J., O.A.W.H., R.B., K.S., and A.A.T. performed research; G.Å.L. and A.A.T. contributed new reagents/analytic tools; P.C.H., R.P.G., J.T.J., O.A.W.H., R.B., K.S., L.A.M., and B.B. analyzed data; and P.C.H. and B.B. wrote the paper.

The authors declare no competing interest.

This article is a PNAS Direct Submission.

This open access article is distributed under [Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 \(CC BY-NC-ND\)](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Data deposition: Sequence Read Archive accession ID [PRJNA495162](https://www.ncbi.nlm.nih.gov/sra/PRJNA495162).

¹To whom correspondence may be addressed. Email: peter.csaba.huszthy@rrr-research.no or bjarne.bogen@medisin.uio.no.

This article contains supporting information online at <https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1902836116/-DCSupplemental>.

First published December 3, 2019.

detectable levels of pId:MHCII. However, BCR ligation induces pId:MHCII display, thereby enabling Id-driven T-B collaboration. The findings support a mechanism where BCR ligation by self antigen is required for display of pId:MHCII on autoreactive B cells and solicitation of help from Id-specific T cells.

Results

A Model System for Studying the Influence of BCR Ligation on Id-Driven T-B Collaboration. The M315 myeloma protein produced by the MOPC315 myeloma cell line binds defined ligands such as anti-Id mAbs (26) and DNP/TNP haptens (27) (Fig. 1A). Its L chain ($\lambda 2^{315}$) contains a mutated Id sequence that spans the V-J junction in the CDR3 loop. Upon antigen processing by APCs, the Id peptide is released and binds to the MHC class II molecule I-E^d for presentation to Id-specific CD4⁺ T cells (3, 4) (Fig. 1A).

To study the role of BCR ligation in Id-driven T-B collaboration, we developed two strains of mice that express the V_H and the V_L of M315, respectively. Upon cross-breeding, the offspring should express an M315-like BCR on a low proportion of their B cells. For the V_H, we made a conventional BCR knock-in mouse where a rearranged and moderately mutated VDJ_H³¹⁵ was placed in the J_H locus (SI Appendix, Figs. S1 and S2A and B). For the V_L,

we generated a type of V gene segment-modified mouse where nine nucleotides encoding the amino terminal part of the mutated Id peptide replaced the corresponding germline nucleotides in the V $\lambda 2$ gene segment (Fig. 1B and SI Appendix, Fig. S3A and B). In rare B cells, where the modified V $\lambda 2^{315m}$ rearranges to the J $\lambda 2$, a recombinant VJ is generated that should encode the entire mutated Id³¹⁵ peptide. The F1 progeny of these two strains, called Id³¹⁵ mice, should express an M315-like BCR on a small subset of their B cells. Such rare Id⁺ B cells were tested for collaboration with Id-specific CD4⁺ T cells from previously described TCR-transgenic mice (28), either in the presence or the absence of BCR ligation by defined ligands (Fig. 1C).

Characterization of Gene-Modified Strains of Mice. In the VDJ_H³¹⁵ mouse, allelic exclusion was pronounced, and VDJ_H³¹⁵ was expressed by most B cells (SI Appendix, Fig. S2C-H). B cell development in the bone marrow was slightly accelerated (SI Appendix, Fig. S3G), as is commonly found in VDJ knock-in mice. In the V $\lambda 2^{315m}$ mouse, codons 94, 95, and 96 of the germline V $\lambda 2$ were exchanged with those of V $\lambda 2^{315}$ expressed by MOPC315. Since the FRT recombination left a short residual sequence within the intron immediately downstream of V $\lambda 2^{315m}$ (SI Appendix, Fig. S3A), the




Fig. 1. A model system for studying the influence of BCR ligation on idiotype-driven T-B collaboration. (A) The M315 monoclonal Ig binds the indicated ligands. The $\lambda 2^{315}$ L chain expresses a mutated CDR3 Id peptide (residues 92 to 100; red triangle) that, after antigen processing, is presented on the MHC class II molecule I-E^d. (B) In V $\lambda 2^{315m}$ mice, the germline V $\lambda 2$ gene segment was modified by the exchange of 9 nucleotides so that the modified V $\lambda 2$ allele encodes the mutated residues F⁹⁴R⁹⁵N⁹⁶ of the central part of the Id sequence. (C) Offspring from a V $\lambda 2^{315m}$ × VDJ_H³¹⁵ cross, called Id³¹⁵ mice (Left), should have a low frequency of B cells with an Id⁺ M315-like BCR that can be deliberately ligated. Id-driven T-B collaboration (Center) can be tested using Id-specific CD4⁺ T cells from previously established TCR-transgenic mice (Right). (D) The prevalence of germ line (YST) and mutated (FRN) sequences in $\lambda 2$ encoding mRNAs in splenic CD19⁺ B cells of heterozygous V $\lambda 2^{315m}$ mice. (E) Map of the V $\lambda 2^{315m}$ → J $\lambda 2$ junction containing the mutated FRN sequence (pink letters) within the minimal Id peptide. The prevalence of various amino acids at the junctional position 98 is indicated. (F) In vitro response (BrdU incorporation) of Id-specific T cells to synthetic peptides with varying junctional residues presented by splenic APCs. (G) Frequency of Id³¹⁵ BCR⁺ B cells in the circulation of Id³¹⁵ and BALB/c mice detected using biotinylated DNP-albumin and $\lambda 2/3$ L chain-specific (2B6 mAb) staining ($n = 5$ per group). (H) Frequency of Id³¹⁵ BCR⁺ B cells detected using anti-Id mAb (Ab2-1.4) that requires association of VDJ_H³¹⁵ and V $\lambda 2^{315m}$ chains for its binding ($n = 10$ Id³¹⁵; $n = 4$ BALB/c). (I and J) DNP-specific (I) or Ab2-1.4-specific (J) antibodies in the sera of Id³¹⁵ and BALB/c mice ($n = 6$ to 9 per group). Statistical comparisons: unpaired t tests (G–J). ** $P \leq 0.01$, *** $P \leq 0.005$.

recombination frequency to $J\lambda 2$ could have been influenced. To test this, we analyzed the frequencies of $V\lambda 2 \rightarrow J\lambda 2$ rearrangements on the WT and $V\lambda 2^{315m}$ chromosomes in heterozygous $V\lambda 2^{315m}$ mice by cDNA amplicon sequencing (29). Both transcripts were expressed, although $V\lambda 2^{315m}$ - $J\lambda 2$ joints were found at a slightly lower frequency than $V\lambda 2$ - $J\lambda 2$ joints (Fig. 1D). At the $V\lambda 2$ - $J\lambda 2$ junction, residue 98 varies due to junctional diversity (30). We found that the rearranged WT and $V\lambda 2^{315m}$ alleles had an identical frequency of different amino acids in position 98 with the ranking order Tyr>>Phe~Leu (Fig. 1E). Since the minimal Id peptide (residues 92 to 100) spans the VJ junction, we tested synthetic peptides with naturally occurring amino acids at position 98 for their ability to stimulate Id-specific CD4⁺ T cells. Peptides with both Tyr⁹⁸ and Phe⁹⁸ residues were fully compatible with stimulation of Id-specific CD4⁺ T cells, while Leu⁹⁸ was not (Fig. 1F). This result indicates that most B cells in which a $V\lambda 2^{315m} \rightarrow J\lambda 2$ rearrangement occurs should potentially be able to stimulate Id-specific T cells. The frequencies and specific lineages of $\lambda 2/3^+$ B cells (detected by a $C\lambda 2/C\lambda 3$ cross-reactive mAb, 2B6) and the levels of total $\lambda 2/3^+$ serum Ig did not differ between $V\lambda 2^{315m}$ and BALB/c mice (SI Appendix, Fig. S3 D–G). These results indicate that the V gene segment modification in $V\lambda 2^{315m}$ did not influence B cell development, so the mouse strain displayed a physiological B cell compartment.

Offspring of homozygous VDJ_H^{315} and $V\lambda 2^{315m}$ mice, called Id^{315} mice, had a slightly accelerated development of B cells in the bone marrow and a small increase in $\lambda 2/\lambda 3^+$ T2 cells in the spleen, but were otherwise normal (SI Appendix, Fig. S3 F and G). These changes are most likely due to the prearranged VDJ_H^{315} component of Id^{315} mice (SI Appendix, Fig. S2A). In Id^{315} mice, ~3 to 4% of circulating B cells expressed an M315-like BCR detected by binding of DNP (Fig. 1G), while ~1.5% were detected by the anti-Id IgG1 Ab2-1.4 (26) (Fig. 1H), consistent with the fine specificity differences between these two BCR ligands (SI Appendix, Table S1) (26) (also detailed later). The result with the highly specific Ab2-1.4 mAb (Fig. 1H) is as expected, since $V\lambda 2^{315m} \rightarrow J\lambda 2$ rearrangements should only occur in ~1 to 2% of peripheral B cells (30). Id^{315} mice had about ~1 to 2 $\mu\text{g/mL}$ of serum IgG that bound DNP (Fig. 1I) and ~0.3 to 0.8 $\mu\text{g/mL}$ that bound anti-Id Ab2-1.4 mAb (Fig. 1J), again consistent with the fine specificity of these reagents (SI Appendix, Table S1) (26). Collectively, these results indicate that VDJ_H^{315} , $V\lambda 2^{315m}$, and Id^{315} mice displayed the expected features.

Id^{315} mice were used in most of the in vivo experiments described herein. However, in some experiments (e.g., adoptive transfers to CD45.1⁺ congenic BALB/c mice), large numbers of Id^{315} B cells (hereafter called Id^+ B cells) were needed. For this purpose, VDJ_H^{315} mice were crossed with previously described $\lambda 2^{315}$ transgenic mice (31). In the progeny, as much as 70 to 80% of peripheral B cells expressed an M315 BCR (SI Appendix, Fig. S4 A and B). In $\lambda 2^{315}TG \times VDJ_H^{315}$ mice, splenic B cells had slightly reduced IgM expression levels (SI Appendix, Fig. S4C), and marginal zone (MZ) B cells were increased relative to follicular (FO) B cells (SI Appendix, Fig. S4D). Nevertheless, Id^+ B cells from the progeny were fully responsive to stimulation. Pre-B and pro-B cells in the bone marrow were reduced, but mature B cells were found to be at normal levels (SI Appendix, Fig. S4E). Since activated B and T cells may modulate their surface antigenic receptors, the use of CD45.1⁺ congenic mice facilitated the detection of the transferred lymphocyte populations upon recovery.

Characterization of Specificity of BCR Ligands. The amino acid exchanges introduced in positions 94, 95, and 96 of $V\lambda 2^{315m}$, as well as the junctional variation in position 98 in $V\lambda 2^{315m}$ - $J\lambda 2$ joints (Fig. 1E), could influence the binding of anti-Id mAb Ab2-1.4 and DNP/TNP used as ligands for the Id^+ BCR (Fig. 1A). To investigate this, we established a panel of recombinant IgGs that express V_H^{315} together with various $V\lambda 2$ -regions and tested

these for binding to the anti-idiotypic mAb Ab2-1.4 as well as DNP and TNP haptens (SI Appendix, Table S1). In brief, the Ab2-1.4 bound V_H^{315} associated with $V\lambda 2^{315m}$ but not with germline $V\lambda 2$. Moreover, Ab2-1.4 binding was compatible with the three most frequent amino acids found in position 98: Tyr, Phe, and Leu (Fig. 1E). The germline equivalent of V_H^{315} , VH3-6*02, was also compatible with binding, while a quite different V_H , V_H^{A20} , was not. However, VH3-6*02 is probably poorly expressed in Id^+ mice due to the prearranged VDJ_H^{315} . In conclusion, Ab2.1.4 is a highly specific ligand for the BCR of Id^+ B cells and should bind all BCRs independent of junctional variation. Its affinity for Id^+ M315 is $K_A = 7.7 \times 10^6 \text{ M}^{-1}$ (32).

TNP and DNP BCR ligands have a broader specificity since either of the haptens bound to V_H^{315} and VH3-6*02 (but not V_H^{A20}) associated with either $V\lambda 2^{315m}$ or $V\lambda 2$ (SI Appendix, Table S1). Junctional variation in position 98 did not influence binding. These results extend a previous study demonstrating that TNP and DNP bind V_H^{315} associated with either $\lambda 1$, $\lambda 2$, and $\lambda 3$ light chains, but not κ light chains (26). Thus, TNP/DNP should bind BCRs that express endogenous λ -chains together with V_H^{315} in Id^{315} mice. The affinity of DNP for M315 has been measured to be in the range of $K_A = 1.6 \times 10^5$ to $3.9 \times 10^6 \text{ M}^{-1}$ (33), and the affinities of DNP and TNP are in a similar range (34).

In the course of the experiments described later, TNP/DNP and Ab2-1.4 were used not only as BCR ligands but also to measure B cell and antibody responses. Somatic hypermutation could have influenced binding and detection, which is difficult to control for. However, this does not seem to have been a major issue, since potent responses were detected by the BCR ligands over prolonged periods of time.

BCR Ligation Is Required for Id-Driven T–B Collaboration in Vitro. We performed a series of in vitro experiments on naive splenic Id^+ B cells enriched through immunomagnetic depletion. Exposure of Id^+ B cells to Ab2-1.4 (hereafter referred to as anti-Id IgG) as BCR ligand resulted in intracellular Ca^{2+} mobilization (Fig. 2A), protein phosphorylation (Fig. 2B), and up-regulation of MHC class II (Fig. 2C) and CD86 (Fig. 2D), but not CD80, cell surface expression. Similar, although slightly lower, responses were obtained with DNP-OVA and TNP-OVA as BCR ligands (SI Appendix, Fig. S5). Importantly, BCR ligation resulted in an increased display of Id peptide–MHC class II complexes on the B cell surface, detected by an scFv reagent specific for the pId^{315} :I-E^d complex [hereafter called pId :I-E^d or pId :MHCII; the reagent detecting this complex is hereafter called a TCR mimetic (TCRm); Fig. 2E; see also SI Appendix, Fig. S6]. Expression of pId :I-E^d was first detected after 18 to 20 h and remained elevated for at least 45 h after ligation (Fig. 2F and SI Appendix, Fig. S6G). When naive Id^+ B cells were mixed with naive Id-specific T cells, BCR ligation induced T cell–B cell conjugate formation within 30 min (Fig. 2G). In cocultures of Id^+ B cells and Id-specific T cells, ligation of the Id^+ BCR by anti-Id IgG resulted in the proliferation of B cells and T cells (Fig. 2H and I). These in vitro results show that BCR ligation enhances Id-driven T–B collaboration and that up-regulation of pId :MHCII is a likely contributor.

It was of interest to assess whether pId :MHCII expression increased only as a consequence of a general up-regulation of MHC class II molecules, and whether BCR ligation was required. To investigate this possibility, Id^+ B cells were BCR-ligated with TNP-OVA and compared with stimulation by the TLR4 ligand LPS (SI Appendix, Fig. S7). LPS stimulation increased the MFI signal of MHCII expression more than 5-fold, whereas pId :MHCII expression was essentially unaltered. The inverse was observed with TNP-OVA as BCR ligand. These results argue that BCR ligation resulted in a specific up-regulation of pId presentation on MHC class II molecules.




Fig. 2. Ligation of the Id⁺ BCR by antigen induces downstream signaling, Id peptide presentation on MHC-II, and stimulation of Id-specific T cells. (A–I) In vitro experiments. Id⁺ B cells (enriched from $\lambda 2^{315}TG \times VDJ_{H}^{315}$ mice by negative selection) were stimulated with anti-Id IgG or added isotype-matched control IgG (10 $\mu\text{g}/\text{mL}$ unless otherwise indicated). (A) Ca^{2+} flux assay. (B) Phosphotyrosine blots of cell lysates. (C–E) MHC-II (I–A^d/I–E^d), CD86, and pId³¹⁵:I–E^d expression after 18 to 21 h in culture. The data represent fold increases in the geometric mean of FI signal of Id⁺ B cells added either anti-Id IgG or isotype control IgG. MFI_G values from nonstimulated Id⁺ B cells in each experiment were taken as a baseline. Fold up-regulation values were pooled from 2 to 3 individual in vitro assays. (F, Left) Histogram plot of pId³¹⁵:I–E^d expression on Id⁺ B cells measured after 48 h using the TCR mimetic scFv reagent. (F, Right) pId³¹⁵:I–E^d presentation on Id⁺ B cells after 21 and 45 h. (G) Conjugate formation between Id⁺ B cells and Id-sp. T cells labeled with CFSE and CTV. (H and I) BrdU incorporation into Id⁺ B cells and Id-specific T cells, measured during the last 14 h of a 4-d coculture. (J–L) In vivo experiments. Id³¹⁵ mice were injected i.v. with 60 μg BCR ligand anti-Id IgG or isotype control IgG, and splenic Id⁺ B cells were analyzed for expression of MHC-II (J), CD86 (K), and pId³¹⁵:I–E^d (L; FACS plots shown in *SI Appendix, Fig. S6F*). Statistical comparisons: unpaired *t* tests (C–E, H, and I), Mann–Whitney *U* tests for BCR ligation versus control at each time point (F), and Dunnett’s multiple comparisons test for baseline levels versus the different time points (J–L). **P* ≤ 0.05, ***P* ≤ 0.01, ****P* ≤ 0.005, and *****P* ≤ 0.001.

BCR Ligation Is Required for Id-Driven T–B Collaboration In Vivo. We first tested the effect of BCR ligation on Id⁺ B cells in vivo in the absence of Id-specific T cells. A cohort of Id³¹⁵ mice were injected i.v. with anti-Id IgG or isotype-matched specificity control mAb, and splenic Id⁺ B cells were analyzed by FACS at the indicated time points. Within 24 to 48 h, BCR ligation enhanced the surface expression of MHC class II molecules, CD86, and pId:MHCII complexes on Id⁺ B cells (Fig. 2 J–L and *SI Appendix, Fig. S6F*). The increased expression was still detectable after 72 h. These results suggest that in vivo provision of BCR ligand prepares Id⁺ B cells for efficient interaction with Id-specific T cells through surface display of both pId:MHCII and costimulatory molecules. Up-regulation of pId:MHCII was observed already at 24 h (Fig. 2L), while a general up-regulation of MHCII was seen first after 48 h (Fig. 2J), again arguing that BCR ligation has a specific contribution to increased display of pId:MHCII.

To probe the sensitivity of the model for Id-driven T–B collaboration, we titrated the amounts of Id-specific T cells, anti-Id IgG, and Id⁺ B cells needed to obtain Id⁺ IgG responses in Id³¹⁵ and in CD45.1 congenic BALB/c recipients. Transfer of 15,000 naive T cells and 4 μg anti-Id IgG sufficed to elicit full Id⁺ IgG responses in Id³¹⁵ recipients (*SI Appendix, Fig. S8A and B*). Even as little as 1,500 Id-specific T cells induced Id⁺ IgG levels above background levels. Assuming a 10 to 15% parking efficiency, this cell dose is estimated to result in a physiological frequency of the Id-specific T cells in the recipient (35). Naive Id⁺ B cells were titrated by transfer into CD45.1⁺ congenic BALB/c mice together with saturating dose of naive Id-specific T cells and anti-Id IgG. About 10⁵ Id⁺ B cells were required to elicit Id⁺ IgG responses (*SI Appendix, Fig. S8C*).

Based on these results, we transferred naive Id-specific T cells and Id⁺ B cells, enriched through immunomagnetic depletion of undesired populations, into CD45.1⁺ congenic BALB/c mice, followed by anti-Id IgG or isotype-matched control IgG and a continuous BrdU administration (Fig. 3A). A number of conclusions could be made based upon analysis of recipient spleens (Fig. 3) and lymph nodes (*SI Appendix, Fig. S9*). In the spleen, BCR

ligation increased the numbers of (i) donor-derived CD45.2⁺ cells (Fig. 3B), (ii) Id-specific CD4⁺ T cells that had incorporated BrdU (Fig. 3C and D), (iii) follicular T helper cells (T_{FH}; Fig. 3E), (iv) Id⁺ B cells that had incorporated BrdU (Fig. 3F), and (v) germinal center (GC) B cells (Fig. 3G). Intracellular staining of recovered Id-specific T cells revealed that BCR ligation increased expression of IFN- γ , TNF- α , and IL-4 cytokines and the transcription factor T-Bet (Fig. 3H), whereas GATA-3 and Foxp3 were not detected. Responses were stronger in the spleen than in the lymph nodes (*SI Appendix, Fig. S9*). BCR ligation induced a 3- to 4-log₁₀ increase in serum levels of Id⁺ IgG of all subclasses (Fig. 3I).

Some of the anti-Id mAb Ab2-1.4 (IgG1) used in the aforementioned experiments could have been internalized via Fc γ RIIb on B cells rather than through receptor-mediated uptake, which could have contributed to pId:MHCII presentation. To exclude this possibility, we generated F(ab)₂ fragments of the anti-Id IgG (*SI Appendix, Fig. S10*). F(ab)₂ fragments were at least as stimulatory as intact anti-Id mAb to initiate Id-driven T–B cell collaboration, demonstrating that the Fc region and uptake via Fc γ RIIb is dispensable for responsiveness to BCR ligation (*SI Appendix, Fig. S11*).

In these experiments, the necessity of BCR ligation for initiation of Id-driven T–B collaboration was demonstrated with naive B and T cells. However, it has been previously demonstrated that naive B cells, although unable to stimulate naive T cells, can stimulate memory T cells (36). Consistent with this, it was shown that naive B cells from $\lambda 2^{315}$ -transgenic mice could stimulate Id-specific Th2 cells in the absence of BCR ligation (37). We therefore tested if naive Id⁺ B cells in Id³¹⁵ mice could collaborate with in vitro-polarized Id-specific Th2 cells after adoptive transfer. The results show that naive Id⁺ B cells can collaborate with Th2 cells in vivo; however, addition of BCR ligation clearly enhanced responses (*SI Appendix, Fig. S12*).

Localization of Id-Driven T–B Collaboration. To study the histological correlates of BCR ligation, we transferred naive Id-specific T cells into Id³¹⁵ mice, injected anti-Id IgG or isotype-matched




Fig. 3. BCR ligation is required for idiotype-driven T–B collaboration in the spleen. (A) Experimental setup (Id-sp. T/anti-Id IgG, $n = 6$; Id-sp. T/isotype control IgG, $n = 4$). (B–G) FACS analysis. The gated populations are shown: B cells, pink gates; T cells, blue gates. (B) Frequencies of donor lymphocytes (CD45.2⁺ CD45.1⁻). (C) Frequencies of Id-specific CD4⁺ T cells detected by the TCR clonotype-specific mAb GB113. (D) BrdU incorporation into Id-specific T cells. (E) Follicular T helper cell differentiation of Id-specific T cells. (F) BrdU incorporation into Id⁺ B cells (CD45.2⁺ B220⁺). (G) Germinal center differentiation of Id⁺ B cells. (H) Intracellular cytokine and intranuclear transcription factor expression by Id-specific CD4⁺ T cells. (I) Serum titers of Id⁺ (anti-Id Ig-reactive) IgG antibody subclasses on day 11. Statistical comparisons: unpaired *t* tests (B–G), Mann–Whitney *U* tests (H and I). * $P \leq 0.05$, ** $P \leq 0.01$, and *** $P \leq 0.005$.

control IgG the next day, and analyzed spleens at different time points after ligation (Fig. 4 and *SI Appendix*, Figs. S13 and S14). Staining of sections for the GL7 lymphocyte activation marker showed that BCR ligation induced a robust extrafollicular activation of B and T cells on day 3 and day 6; however, activation had considerably subsided by day 9. Germinal centers (GCs) also peaked early (day 3), but these still remained on day 9, although they were fewer (*SI Appendix*, Fig. S13A and Fig. 4D; further detail provided later). By immunofluorescence analysis using mAbs specific for the Id⁺ BCR, the Id-specific TCR, the follicular dendritic cell light zone marker CD35, and GL7, we found considerable numbers of Id⁺ B cells and Id-specific T cells localized in regions surrounding GL7⁺/CD35⁺ GCs. Moreover, direct contacts (synapses) were observed between Id⁺ B cells and Id-specific T cells outside GCs (Fig. 4B and *SI Appendix*, Fig. S14A). GL7⁺ GC B cells stained only weakly with Ab2-1.4 anti-Id mAb (*SI Appendix*, Fig. S14B, *Top*), most likely due to BCR down-regulation. In contrast, stronger staining for the Id⁺ Ig, sometimes suggestive of cytosolic accumulation, was detected in B cells outside the GC (Fig. 4B and *SI Appendix*, Fig. S14A). In addition to their predominantly extrafollicular location, Id-specific T cells were also observed, albeit more scarcely, in the GC (Fig. 4B and *SI Appendix*, Fig. S14B). Staining for Ki-67 corroborated that proliferation oc-

curred both in GCs and in extrafollicular B cell clusters on day 3 postligation (*SI Appendix*, Fig. S14C).

Quantification revealed that BCR ligation increased specific T–B synapses as well as GCs in spleen sections (Fig. 4C and D). Synapses as well as GCs were most frequent already on day 3, and declined thereafter (Fig. 4C and D). Synapses and GC formation preceded the peak expansion of Id⁺ B cells (day 6; Fig. 4E) and the peak of Id⁺ serum IgG (Fig. 4F). In summary, Id-driven T–B collaboration appeared to occur predominantly in extrafollicular sites and to a smaller extent in GCs. The latter appeared small and of short duration, perhaps indicative of abortive GC reactions. Analysis of stained sections (Fig. 4B and *SI Appendix*, Figs. S13 and S14) revealed less robust GC responses than did the FACS analysis (Fig. 3), where a preponderance of GC B cells and T_{FH} was found. Of note, for the FACS analyses, we used the CD45.2 congenic marker, which is expressed irrespective of downmodulation of the BCR or the TCR, thereby facilitating recovery and enumeration of a larger proportion of the transferred cells. Furthermore, the anatomical location of Id⁺ B cells could differ in Id³¹⁵ mice (natural positioning) compared to their location after injection i.v. into CD45.1 congenic recipients, thereby influencing the results.




Fig. 4. Germinal centers form rapidly in Id³¹⁵ mice upon ligation of the Id⁺ BCR. (A) Experimental setup (Id-sp. T/anti-Id IgG, $n = 14$; Id-sp. T/isotype control IgG, $n = 4$). (B) Representative germinal center in the spleen of a recipient mouse on day 3. Id-specific TCR (donotype-specific mAb GB113, red) and Id⁺ BCR (anti-Id BCR Ab2-1.4 mAb, blue) staining shows an area of T cell–B cell interaction. Germinal center B cells were identified as GL7⁺ clusters (green) with the light zone indicated by the presence of follicular dendritic cells (CD35, white). Examples of T–B synapses are magnified in 1 and 2. *SI Appendix, Fig. S14B* shows single stains contributing to the overlay. (C) Quantification of specific T–B synapses based on transgenic receptor expression in sections. Each data point represents the number of Id⁺ B/Id-sp. T synapses counted in one $\times 20$ field. (D) Quantification of germinal centers from spleen cryosections (means per $\times 10$ field). (E) Id⁺ B cells (Ab2-1.4-reactive) among κ light chain negative splenic B cells by FACS analysis. (F) Id⁺ IgG serum levels. (G) Frequencies of the different λ transcripts recovered among PNA⁺ and PNA⁻ fractions of sorted B cells. The B cells were sorted on day 7 from spleens of Id³¹⁵ mice primed with Id-specific T cells and anti-Id F(ab)₂ fragments (*SI Appendix, Fig. S11*). (H) Comparisons of mutational load among V λ 2^{315m}-J λ 2 L chain transcripts recovered from the PNA-positive and PNA-negative fractions. Statistical comparisons: Dunnett’s multiple comparisons test (C and D), unpaired *t* tests (E, F, and H). * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.005$, and **** $P \leq 0.001$; n.s., not significant.

Analysis of Id-Driven T–B Collaboration by Ig Gene Sequencing. On day 7 of Id-driven T–B collaboration, using anti-Id F(ab)₂ fragments as BCR ligand (*SI Appendix, Fig. S11*), we purified PNA⁺ and PNA⁻ B cells from Id³¹⁵ mouse spleens and PCR-amplified

and sequenced light chain transcripts with primers specific for $\lambda 1$, $\lambda 2$, and $\lambda 3$ chains. The PNA⁺ fraction contained 20% GL7⁺ CD95⁺ cells by FACS, indicating ~ 15 fold enrichment of GC B cells. Sequence analysis showed that the PNA⁺ population was almost completely dominated by V λ 2^{315m} sequences having the idiotypic FRN sequence in positions 94 to 96 (Fig. 4G). A similar but less pronounced result was obtained for the PNA⁻ population. These observations demonstrate a strong expansion of V λ 2^{315m+} B cells, not only in the GC (PNA⁺) population, but also in the non-GC (PNA⁻) population. The results support the functional data (Figs. 3 and 4). Interestingly, the junctional amino acid in V λ 2^{315m}-J λ 2 sequences was exclusively F⁹⁸ even though Y⁹⁸ was by far the most frequent junctional residue in V λ 2^{315m}-J λ 2 sequences of unstimulated B cells (Fig. 1E). The level of nucleotide substitutions was surprisingly low, with most sequences being unmutated or having only one mutation (Fig. 4H and *SI Appendix, Fig. S15*). The level of nucleotide substitutions in V λ 2^{315m}-J λ 2 transcripts was not significantly different between the PNA⁺ population and the PNA⁻ population (Fig. 4H). The paucity of mutations in the PNA⁺ cell population is surprising and appears consistent with a limited GC response.

Ligation of the Id⁺ BCR Using a Hapten–Protein Conjugate Promotes Id-Driven T–B Collaboration. M315 has a specificity for the structurally similar haptens DNP and TNP (27), but does not bind the NIP hapten. We therefore tested if BCR ligation by DNP- and TNP-conjugated proteins could promote Id-driven T–B collaboration. CD45.1⁺ BALB/c mice were transferred with Id⁺ B cells and Id-specific T cells, followed by TNP-OVA or NIP-OVA (specificity control). Thereafter, mice continuously received BrdU (Fig. 5A). High doses of hapten–OVA conjugates were used (200 μ g), since preliminary experiments suggested that DNP-OVA is relatively inefficient at promoting Id-driven T–B collaboration in vivo compared to anti-Id IgG (*SI Appendix, Fig. S16*). Several factors could contribute to this difference. First, OVA is filtrated in the kidneys (38), while the higher-MW anti-Id IgG is not. Second, B cells expressing VDJ_H³¹⁵ together with other λ chains than λ 2^{315m} could bind DNP/TNP conjugates (*SI Appendix, Table S1*) and thus serve as a sink for DNP/TNP-OVA. Finally, the Ig structure of the anti-Id IgG ligand could be particularly efficient at cross-linking BCR due to matching distances between antigen binding sites of Id⁺ and anti-Id IgG.

Despite the decreased sensitivity, BCR ligation by TNP-OVA in vivo increased BrdU incorporation into both Id-specific T cells and Id⁺ B cells compared to that seen with NIP-OVA (Fig. 5B and C). Further, BCR ligation increased the frequency of GC-like Id⁺ B cells (Fig. 5D). Finally, BCR ligation enhanced the serum levels of Id⁺ IgG of all subclasses (Fig. 5E). These results show that BCR ligation with TNP-OVA enhances Id-driven T–B collaboration.

BCR Ligation with a T Cell-Independent Type 2 Antigen Enhances Id-Driven T–B Collaboration. In the experiments described here earlier, endogenous T cell responses directed against the BCR ligand, either anti-Id IgG or OVA, could have influenced the results. To exclude this possibility, we tested DNP-FICOLL as a BCR ligand, the rationale being that FICOLL is a polysaccharide that should not be presented on MHC class II molecules to endogenous T cells. Moreover, since DNP-FICOLL is a T cell-independent type 2 (TI-2) antigen, the experiment addresses whether Id-specific CD4⁺ T cells influence B cell responses to a TI-2 antigen.

Id-specific T cells were transferred to Id³¹⁵ mice followed by DNP-FICOLL or NIP-FICOLL the next day (Fig. 6A). Responses in the spleens were analyzed on day 10. Immunohistochemical staining revealed an enhanced generation of GCs on day 10 when using DNP-FICOLL compared to NIP-FICOLL (Fig. 6B), which was verified by quantitative assessment (Fig. 6C). In the absence of T cell help, BCR ligation by DNP-FICOLL elicited a slight




Fig. 5. Ligation of the Id⁺ BCR by TNP-OVA enables Id-driven T–B collaboration. (A) Experimental setup ($n = 5$ Id⁺ B/Id-sp. T/TNP-OVA; $n = 4$ Id⁺ B/Id-sp. T/NIP-OVA). (B–D) FACS analysis. The gated populations are shown; B cells, pink gates; T cells, blue gates. (B) BrdU⁺ Id-specific T cells among transferred T cells. (C) BrdU⁺ donor B cells. (D) Id⁺ GC (CD38^{lo}) B cells. (E) Serum titers of Id⁺ IgG antibody subclasses on day 7. Statistical comparisons: unpaired *t* tests (B–D), Mann–Whitney *U* test (E). * $P \leq 0.05$, ** $P \leq 0.01$.

expansion of Id⁺ (λ⁺) B cells, including GC B cells and plasma cells, as determined by flow cytometry (Fig. 6D and E and *SI Appendix*, Fig. S17). Addition of Id-specific T cells enhanced the expansion of Id⁺ B cells and promoted their differentiation into GC B cells and plasma cells (Fig. 6D and E and *SI Appendix*, Fig. S17). Finally, the concentrations of serum IgM and IgG that bound anti-Id mAb or DNP were enhanced in the presence of DNP-FICOLL and Id-specific T cell help compared to control groups (Fig. 6F). Taken together, the results show that a TI-2 BCR ligand alone stimulates Id⁺ B cell responses weakly, but that provision of Id-specific T cell help significantly augments responses. Further, recognition of the BCR ligand by endogenous polyclonal T cells is not required for Id-driven T–B collaboration.

To test if the CD40L–CD40 axis was involved in Id-driven T–B collaboration, we next tried to block responses to DNP-FICOLL by repetitive injections of anti-CD40L mAb (Fig. 6G and *SI Appendix*, Fig. S18). The results show that CD40L blockade increased the levels of Id⁺ IgM while Id⁺ IgG of all subclasses were

decreased (Fig. 6G and *SI Appendix*, Fig. S18). Thus, CD40L is involved in the IgM → IgG switch in the presence of Id⁺ B and Id-specific T cells. Anti-CD40L mAb did not inhibit the IgM response by Id⁺ B cells induced by DNP-FICOLL in the absence of Id-specific T cells, consistent with DNP-FICOLL being a TI-2 antigen (*SI Appendix*, Fig. S19).

The experiment was extended to adoptive transfer of Id⁺ LPS blasts and naïve Id-specific T cells to CD45-congenic recipients, followed by injection of DNP-FICOLL (*SI Appendix*, Fig. S20A). BCR ligation enhanced responses of Id⁺ LPS blasts, both in terms of plasma cell differentiation and IgG production (*SI Appendix*, Fig. S20C–E). A slight expansion of Id-specific T cells was observed in response to LPS blasts in the absence of ligation (*SI Appendix*, Fig. S20B), but this did not result in IgG serum levels above that observed in mice transferred LPS blasts only (*SI Appendix*, Fig. S20D and E). These results indicate that nonspecific activation of Id⁺ B cells through TLR4 is not sufficient to induce collaboration with naïve Id-specific T cells, but that BCR ligation is required. This may well relate to the importance of recognition of pId:MHCII by Id-specific T cells, since the level of pId:MHCII remained unchanged after LPS stimulation (*SI Appendix*, Fig. S7).

Ligation of the Id⁺ BCR Promotes the Development of Memory B Cells, Bone Marrow Plasma Cells and Id-Specific Regulatory T Cells.

After having evaluated early responses to BCR ligation, we performed experiments where responses were analyzed at later time points, e.g., day 28 (*SI Appendix*, Fig. S21). Id⁺ B cells and Id-specific T cells were transferred to CD45.1⁺ BALB/c mice followed by specific BCR ligation (DNP-FICOLL) or nonspecific control antigen (NIP-FICOLL). Four weeks later, the spleens and bone marrow cells from femurs were analyzed (*SI Appendix*, Fig. S21A). Id-specific regulatory T cells were found on day 28, and had increased to ~2% of recovered Id-specific T cells in the spleen (*SI Appendix*, Fig. S21B). The development of Tregs required BCR ligation. Formation of Id⁺ memory B cells (CD73⁺ CD273⁺) in the presence of BCR ligation was also increased (*SI Appendix*, Fig. S21C). Finally, bone marrow plasma cells were significantly expanded in recipients that had received the BCR ligand (*SI Appendix*, Fig. S21D), and serum antibodies specific for anti-Id IgG and DNP were significantly elevated (*SI Appendix*, Fig. S21E–H). Id⁺ plasma cells secreting Id⁺ IgM and Id⁺ IgG were also found on day 40 in another experiment, where anti-Id IgG was used as BCR ligand (*SI Appendix*, Fig. S22). These results show that BCR ligation in Id-driven T–B collaboration has a long-lasting influence.

Discussion

The present results demonstrate that BCR V region-derived Id peptides are undetectable on MHC class II molecules of naïve B cells, but that BCR ligation induces display. Further, in the presence of naïve Id-specific CD4⁺ T cells, BCR ligation initiates the full panoply of events of T cell–B cell collaboration, including T–B synapse formation, mutual activation and proliferation, GC formation with generation of GC B cells and T_{FH}, extrafollicular T–B cell responses, and an increase in plasma cells and antibody production. Despite the expansion of Id⁺ B cells, the level of mutations in their BCR L chain V region was surprisingly small. Whether BCR-ligated Id-driven T–B cell collaboration requires dendritic cells has not been addressed in the current work, although DCs were dispensable during conventional T–B collaboration using anti-Id BCR knock-in mice and Id⁺ M315 as antigen (39).

These results seemingly contradict previous functional studies in mice (4, 5, 37) and MHCII elution studies in mice (6) and humans (23, 24, 40), which have demonstrated spontaneous pId:MHCII presentation without deliberate BCR ligation. However, these previous studies employed malignant B cells of unknown specificity cultured *in vitro*, and a number of uncontrolled factors could have contributed to constitutive pId:MHCII display. In more




Fig. 6. B cell responses to a BCR-specific T-independent type-2 antigen is enhanced by Id-specific T cells. (A) Experimental setup ($n = 5$ Id-sp. T/DNP-FICOLL; $n = 5$ Id-sp. T/NIP-FICOLL; $n = 3$ DNP-FICOLL). Spleens were analyzed by IHC (B and C) or by FACS (D and E). (B) Representative cryosection from a recipient mouse spleen immunostained using anti- λ BCR L chain Alexa Fluor 488 (green), peanut agglutinin Alexa Fluor 594 (red), and rat anti-mouse reticular fiber Ab (ER-TR7, blue). (C) GCs quantified from immunostained spleen sections. (D) Germinal center B cells. GL7⁺ cells with λ L chains were gated among IgD⁻ B cells (SI Appendix, Fig. S17). (E) Plasma cells (CD138⁺) among splenocytes. (F) Serum concentrations of anti-Id Ig-reactive IgM, IgG, and DNP-reactive IgG on day 10. (G) CD40L blockade by repetitive injection of anti-CD40L mAb or isotype-matched control. Effects on serum levels of Id⁺ IgM (day 5) and IgG1 (day 7). A detailed description and analysis is given in SI Appendix, Fig. S18. Statistical comparisons: Tukey's multiple comparisons tests (C–E), Dunn's multiple comparisons test (F and G). * $P \leq 0.05$, ** $P \leq 0.01$, and *** $P \leq 0.005$.

physiologically relevant experiments, naive B cells from $\lambda 2^{315}$ Ig L-transgenic mice stimulated Id-specific Th2 cells, but not naive Id-specific CD4⁺ T cells (37). In a second Ig L-chain transgenic model, B cells had to be activated in order to stimulate Id-specific T cell hybridomas in vitro (41). In these studies, the Ig L chain transgenic B cells had a polyclonal H chain repertoire, thus making it difficult to exclude a contribution of BCR ligation by unknown antigens to pId:MHCII display. The present study removes many of the ambiguities of these previous studies. First, a V gene segment-modified mouse was created that had a low frequency of B cells, which, subsequent to a $V\lambda 2 \rightarrow \lambda 2$ rearrangement, had a physiological expression of a defined Id sequence in the BCR L chain. Second, these Id⁺ B cells expressed a defined H chain (from VDJ_H knock-in mice), and thus had a BCR of known specificity, equivalent to that of myeloma protein M315. Third, naive Id⁺ B cells and naive Id-specific T cells were employed. Fourth, relatively low (but still unphysiological [35]) numbers of B and T cells were used in the cell transfer experiments. Fifth, three different BCR ligands, including a TI-2 ligand, were employed, with similar results. Sixth, display of pId:MHCII was physically measured by a staining reagent, in addition to functional readouts.

The mechanism by which BCR ligation by antigen enhances pId:MHCII expression is unknown, but is most likely due to enhanced endocytosis and processing of ligated BCR. Thus, we propose that ligation not only induces endocytosis, processing, and presentation of Ag (42) but also of the BCR itself. This makes sense, since the BCR and Ag components of the BCR–Ag complex should follow the same track in the endocytic pathway and should therefore be exposed to the same proteolytic enzymes in

endosomes. The idea is consistent with antigen receptor-directed antigen “handover” to class II MHC molecules with the addition that BCR fragments are also generated and transferred (43, 44). Cathepsins L and S have been described to be involved in proteolytic fragmentation of Ag (45) and may also be involved in processing of the BCR. Interesting in this respect, in silico analysis indicated that Cathepsin B, L, and S sites are enriched within and immediately upstream of CDR3 regions in intrathecal IgG from multiple sclerosis patients (21). This observation suggests that CDR3 peptides could be preferentially released by antigen processing of the BCR in endosomes.

However, other possibilities for the cellular origin of the pId component of the pId:MHCII complex cannot be excluded. It has previously been described that nascent Ig L chains experimentally retained in the ER/Golgi can be the source of pId displayed on MHCII of transfected B lymphoma cells (5). Since BCR ligation resulted in an up-regulated expression of MHCII, this mechanism could possibly increase the display of pId derived from ER/Golgi. Moreover, since BCR ligation enhanced levels of costimulatory molecules, pId:MHCII complexes on B cells could more potently elicit T cell responses.

Ligation-induced display of pId:MHCII on B cells could be of importance in immune regulation. Thus, whenever Ag ligates the BCR of a B cell, that B cell is anticipated to display both pAg:MHCII and pId:MHCII complexes and thus be regulated by both Ag-specific and Id-specific T cells. Such a mechanism would effectively merge conventional (42, 46) and Id-driven (7, 13) T–B collaboration.

The observation that DNP- and TNP-conjugated OVA were somewhat less potent at inducing B cell responses than was anti-Id

IgG may be related to the slightly lower affinity of the haptens for the Id⁺ BCR. Further, filtration of TNP/DNP-OVA in the kidney, and a binding of TNP/DNP to BCRs having irrelevant (non-Id) λ chains, could also contribute. DNP-FICOLL was highly efficient, but this may relate to the TI-2 nature of FICOLL. It should be noted that DNP-FICOLL elicited much more potent responses in the presence of Id-specific T cells, even when employing LPS-stimulated B cells.

It has been hypothesized that Id-driven T–B collaboration could cause development of autoimmune diseases, since autoreactive B cells that have their BCR ligated by autoantigen could receive help from Id-specific T helper cells (13, 25). Such Id-driven T–B collaboration could easily become chronic, since self-antigens are not readily eliminated, in contrast to exogenous antigens. The persistent nature of Id-driven T–B collaboration could cause development of autoimmune diseases and, after acquisition of oncogenic events, B cell lymphomas. Supporting the hypothesis, chronic Id-driven T–B collaboration has been shown to elicit SLE-like disease in mice (16, 25), with hallmarks of human SLE (15). Moreover, Id-driven T–B collaboration has been associated with multiple sclerosis in humans (19–21). Finally, chronic Id-driven T–B collaboration initiated development of B cell lymphomas in mice (17) and possibly CLL in humans (22). The influence of BCR ligation could not be addressed in these studies. Here, in support of the hypothesis, we demonstrate that BCR ligation is required for efficient Id-driven T–B cell collaboration. This suggests that (i) chronic ligation of the BCR by autoantigen and (ii) persistent help from Id-specific T cells may synergize in causing chronic proliferation of B cells and the development of disease. This scenario is consistent with the observations that not only autoimmune diseases (47) but also B cell cancers (48–51) are associated with self-reactive BCRs. It should be stressed that the hypothesis relates to the induction of B cell disorders. In later phases of the disease, the requirement for BCR ligation and for Id-specific T cell help could diminish as the pathologic B cells attain an increasingly autonomous state.

Autoimmune diseases and B cell malignancies are relatively rare disorders. Therefore, in most individuals, Id-driven T–B collaboration does not escalate beyond control but is down-regulated over time. Such down-modulation might occur through a number of suppressive mechanisms, such as peripheral exhaustion of Id-specific T cells (52), deletion of Id-specific thymocytes (12), and perhaps through the action of Id-specific T suppressor cells (53). We here demonstrate the induction of Foxp3⁺ Id-specific regulatory T cells in the wake of Id-driven T–B collaboration; such cells

could contribute to down-regulation of the response. Presumably, only when one or more of these suppressive mechanisms fail may unchecked Id-driven T–B collaboration result in development of autoimmunity and B cell cancers.

Experimental Outline. Extended materials and methods have been added at the end of the *SI Appendix* after *SI Appendix, Table S1* (p. 37–41). *SI Appendix* describes the generation of VDJ_H³¹⁵ mice (*SI Appendix, Fig. S2*, p. 5) and V λ 2^{315m} mice (*SI Appendix, Fig. S3*, p. 7). Pages 7 and 8 describe the Id³¹⁵ and λ 2³¹⁵ TG \times VDJ_H³¹⁵ mice. Page 7 describes FACS characterization of splenic and bone marrow B cell lineages. *SI Appendix, Fig. S6* (p. 13) shows generation of the anti-pId³¹⁵:I-E^d scFv. *SI Appendix, Fig. S10* (p. 17) shows preparation and validation of the anti-Id F(ab)₂. *SI Appendix, Figs. S13 and S14* show GL7 immunostaining (p. 21) and immunofluorescence (p. 23) procedures. *SI Appendix, Fig. S15* (p. 26) shows germinal center B cell sorting and sequencing procedures. Cell enrichment, in vitro stimulation cultures, and in vivo transfer experiments are described in *SI Appendix, Extended Materials and Methods* (p. 37–38). ELISAs for Id⁺ IgM and IgG are described in *SI Appendix, Extended Materials and Methods* (p. 38–39). All antibodies for flow cytometry are described in *SI Appendix, Extended Materials and Methods* (p. 39). λ Amplicon sequencing in naïve V λ 2³¹⁵ mice is described in *SI Appendix, Extended Materials and Methods* (p. 39). Analyses of in vitro B cell responses, including of Ca²⁺ flux measurements, and phosphotyrosine Western blotting are described in *SI Appendix, Extended Materials and Methods* (p. 40).

Data and Materials Availability. The V-gene modified mice and the TCRm reagent may be obtained on a collaborative basis. Sequencing raw data from λ amplicon sequencing from the V λ 2^{315m/+} mouse are available at the Sequence Read Archive. Identifiers are BioSample SAMN10220898; sample name, VL2-315 B^{+/-}; SRA, SRS3891429; BioProject, PRJNA495162.

ACKNOWLEDGMENTS. Hilde Omholt, Peter Hofgaard, Keith M. Thompson, Marte Fauskanger, Kristina Randjelovic, Elisabeth Vikse, Nicolay Rustad Nilssen, and Olaf F. Schreurs are thanked for technical help; Vegard Nygaard and Eivind Hovig at the Oslo University Hospital Bioinformatics Core Facility for help with analyzing sequence data; Omri Snir for help with mRNA QC; and the staff at the Department of Comparative Medicine, Rikshospitalet, for assistance with mouse experiments. We are indebted to Drs. Robert Bremel and Jane Homan for critically reviewing the manuscript. Funding: The Norwegian Research Council (NFR, project 221709, to B.B.) and South-East Health Authority (Helse Sør-Øst, project 2017082, to B.B.) are acknowledged for funding.

1. S. Tonegawa, Somatic generation of antibody diversity. *Nature* **302**, 575–581 (1983).
2. S. Sirisinha, H. N. Eisen, Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. *Proc. Natl. Acad. Sci. U.S.A.* **68**, 3130–3135 (1971).
3. B. Bogen, B. Malissen, W. Haas, Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. *Eur. J. Immunol.* **16**, 1373–1378 (1986).
4. S. Weiss, B. Bogen, B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. *Proc. Natl. Acad. Sci. U.S.A.* **86**, 282–286 (1989).
5. S. Weiss, B. Bogen, MHC class II-restricted presentation of intracellular antigen. *Cell* **64**, 767–776 (1991).
6. A. Yu. Rudensky, P. Preston-Hurlburt, B. K. al-Ramadi, J. Rothbard, C. A. Janeway, Jr, Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs. *Nature* **359**, 429–431 (1992).
7. B. Bogen, S. Weiss, Processing and presentation of idiotypes to MHC-restricted T cells. *Int. Rev. Immunol.* **10**, 337–355 (1993).
8. B. Bogen, T. Jørgensen, K. Hannestad, T helper cell recognition of idiotopes on lambda 2 light chains of M315 and T952: Evidence for dependence on somatic mutations in the third hypervariable region. *Eur. J. Immunol.* **15**, 278–281 (1985).
9. B. Bogen, J. D. Lambris, Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule. *EMBO J.* **8**, 1947–1952 (1989).
10. M. C. Eyerman, L. Wysocki, T cell recognition of somatically-generated Ab diversity. *J. Immunol.* **152**, 1569–1577 (1994).
11. M. C. Eyerman, X. Zhang, L. J. Wysocki, T cell recognition and tolerance of antibody diversity. *J. Immunol.* **157**, 1037–1046 (1996).
12. B. Bogen, Z. Dembic, S. Weiss, Clonal deletion of specific thymocytes by an immunoglobulin idotype. *EMBO J.* **12**, 357–363 (1993).
13. L. A. Munthe, A. Os, M. Zangani, B. Bogen, MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. *J. Immunol.* **172**, 7476–7484 (2004).
14. C. M. Snyder *et al.*, Activation and tolerance in CD4(+) T cells reactive to an immunoglobulin variable region. *J. Exp. Med.* **200**, 1–11 (2004).
15. K. Aas-Hanssen, A. Funderud, K. M. Thompson, B. Bogen, L. A. Munthe, Idiotope-specific Th cells support oligoclonal expansion of anti-dsDNA B cells in mice with lupus. *J. Immunol.* **193**, 2691–2698 (2014).
16. M. Zangani *et al.*, Tracking early autoimmune disease by bioluminescent imaging of NF-kappaB activation reveals pathology in multiple organ systems. *Am. J. Pathol.* **174**, 1358–1367 (2009).
17. M. M. Zangani *et al.*, Lymphomas can develop from B cells chronically helped by idotype-specific T cells. *J. Exp. Med.* **204**, 1181–1191 (2007).
18. R. D. Bremel, E. J. Homan, Frequency patterns of T-cell exposed amino acid motifs in immunoglobulin heavy chain peptides presented by MHCs. *Front. Immunol.* **5**, 541 (2014).
19. A. L. Hestvik *et al.*, T cells from multiple sclerosis patients recognize multiple epitopes on Self-IgG. *Scand. J. Immunol.* **66**, 393–401 (2007).
20. T. Holmøy, F. Vartdal, A. L. Hestvik, L. Munthe, B. Bogen, The idotype connection: Linking infection and multiple sclerosis. *Trends Immunol.* **31**, 56–62 (2010).
21. R. A. Høglund *et al.*, *In silico* prediction analysis of idotope-driven T-B cell collaboration in multiple sclerosis. *Front. Immunol.* **8**, 1255 (2017).
22. A. Os *et al.*, Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. *Cell Rep.* **4**, 566–577 (2013).

23. M. S. Khodadoust *et al.*, Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. *Nature* **543**, 723–727 (2017).
24. M. S. Khodadoust *et al.*, B cell lymphomas present immunoglobulin neoantigens. *Blood* **133**, 878–881 (2019).
25. L. A. Munthe, A. Corthay, A. Os, M. Zangani, B. Bogen, Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells. *J. Immunol.* **175**, 2391–2400 (2005).
26. G. Kristoffersen, K. Hannestad, T. Hansen, Two M315 idiotopes defined by isologous monoclonal antibodies: One depends on germline and the other on mutated murine lambda 2 light chain sequences. *Scand. J. Immunol.* **26**, 535–546 (1987).
27. H. N. Eisen, E. S. Simms, M. Potter, Mouse myeloma proteins with antihapten antibody activity. The protein produced by plasma cell tumor MOPC-315. *Biochemistry* **7**, 4126–4134 (1968).
28. B. Bogen, L. Gleditsch, S. Weiss, Z. Dembic, Weak positive selection of transgenic T cell receptor-bearing thymocytes: Importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. *Eur. J. Immunol.* **22**, 703–709 (1992).
29. P. C. Huszthy, R. P. Gopalakrishnan, B. Bogen, Lambda amplicon sequencing in V-gene modified mice that express the MOPC315 Idiotope. NCBI Sequence Read Archive. <https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA495162>. Deposited 9 October 2018.
30. H. N. Eisen, E. B. Reilly, Lambda chains and genes in inbred mice. *Annu. Rev. Immunol.* **3**, 337–365 (1985).
31. B. Bogen, S. Weiss, A rearranged lambda 2 light gene chain retards but does not exclude kappa and lambda 1 expression. *Eur. J. Immunol.* **21**, 2391–2395 (1991).
32. J. T. Jacobsen *et al.*, B-cell tolerance to the B-cell receptor variable regions. *Eur. J. Immunol.* **43**, 2577–2587 (2013).
33. T. Azuma, N. Sakato, H. Fujio, Characterization of the combining site of mouse myeloma protein M315. *Biochemistry* **27**, 6116–6120 (1988).
34. S. K. Dower, P. Gettins, R. Jackson, R. A. Dwek, D. Givol, The binding of 2,4,6-trinitrophenyl derivatives to the mouse myeloma immunoglobulin A protein MOPC 315. *Biochem. J.* **169**, 179–188 (1978).
35. J. J. Moon *et al.*, Tracking epitope-specific T cells. *Nat. Protoc.* **4**, 565–581 (2009).
36. F. Ronchese, B. Hausmann, B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes. *J. Exp. Med.* **177**, 679–690 (1993).
37. L. A. Munthe, J. A. Kyte, B. Bogen, Resting small B cells present endogenous immunoglobulin variable-region determinants to idiotope-specific CD4(+) T cells in vivo. *Eur. J. Immunol.* **29**, 4043–4052 (1999).
38. M. G. Lawrence *et al.*, Permeation of macromolecules into the renal glomerular basement membrane and capture by the tubules. *Proc. Natl. Acad. Sci. U.S.A.* **114**, 2958–2963 (2017).
39. J. Jacobsen *et al.*, Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells. *J. Immunol.* **192**, 4174–4183 (2014).
40. R. M. Chic *et al.*, Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. *J. Exp. Med.* **178**, 27–47 (1993).
41. C. M. Snyder, X. Zhang, L. J. Wysocki, Negligible class II MHC presentation of B cell receptor-derived peptides by high density resting B cells. *J. Immunol.* **168**, 3865–3873 (2002).
42. A. Lanzavecchia, Antigen-specific interaction between T and B cells. *Nature* **314**, 537–539 (1985).
43. H. W. Davidson, C. Watts, Epitope-directed processing of specific antigen by B lymphocytes. *J. Cell Biol.* **109**, 85–92 (1989).
44. C. Watts, The endosome-lysosome pathway and information generation in the immune system. *Biochim. Biophys. Acta* **1824**, 14–21 (2012).
45. C. S. Hsieh, P. deRoos, K. Honey, C. Beers, A. Y. Rudensky, A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. *J. Immunol.* **168**, 2618–2625 (2002).
46. N. A. Mitchison, The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. *Eur. J. Immunol.* **1**, 18–27 (1971).
47. C. G. Vinuesa, I. Sanz, M. C. Cook, Dysregulation of germinal centres in autoimmune disease. *Nat. Rev. Immunol.* **9**, 845–857 (2009).
48. R. M. Young *et al.*, Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. *Proc. Natl. Acad. Sci. U.S.A.* **112**, 13447–13454 (2015).
49. M. Hervé *et al.*, Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. *J. Clin. Invest.* **115**, 1636–1643 (2005).
50. C. C. Chu *et al.*, Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: Implications for patient outcome and cell of origin. *Blood* **115**, 3907–3915 (2010).
51. R. Catera *et al.*, Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. *Mol. Med.* **14**, 665–674 (2008).
52. B. Bogen, Peripheral T cell tolerance as a tumor escape mechanism: Deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. *Eur. J. Immunol.* **26**, 2671–2679 (1996).
53. R. A. Heiser, C. M. Snyder, J. St Clair, L. J. Wysocki, Aborted germinal center reactions and B cell memory by follicular T cells specific for a B cell receptor V region peptide. *J. Immunol.* **187**, 212–221 (2011).